ArticleJournal of translational medicine2026
Integrated transcriptomic and metabolomic profiling reveals immune-metabolic crosstalk and predictive biomarkers of ligustrazine treatment response in idiopathic pulmonary fibrosis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by aberrant immune responses and tissue remodeling. Ligustrazine has multiple effects, such as enhancing immunity and alleviating cellular hypoxia, and can improve pulmonary fibrosis. However, the underlying immune–metabolic interactions and predictive molecular biomarkers remain poorly defined. Understanding the mechanisms underlying therapeutic response is critical for developing precision medicine approaches.
methodsWe performed an integrative analysis using data from a rat model and humans, including bulk and single-cell transcriptomics (GSE150910, GSE32537, GSE122960) and untargeted metabolomics, to identify differentially expressed genes and metabolites associated with IPF and therapeutic intervention with ligustrazine. Key genes (IPFGs) and metabolites (IPFMs) were identified on the basis of their expression and correlation profiles. Consensus clustering was applied to stratify IPF molecular subtypes, and biological function differences between different clusters were further explored through ssGSEA. GSEA, miRNA and transcription factor (TF) network prediction, and single-cell analysis were performed to characterize the functional roles and regulatory mechanisms of key IPFGs. Diagnostic nomograms were constructed based on key IPFGs and related immune cell subsets and were evaluated by receiver operating characteristic (ROC) curve analysis.
resultsFive key IPFGs (CCL2, UBD, TIGIT, SYDE2, and COL4A3) and eight IPFMs (O−[(9Z) − 17 − Carboxyheptadec − 9 − enoyl]carnitine; LPE O − 17:0; PC 16:1_19:1; sodium deoxycholate; alloursodeoxycholic acid; prostaglandin F2α alpha−carissanol; and aspartame) were significantly altered across the IPF, treatment and control groups and strongly correlated with immune cell infiltration, particularly with activated dendritic cells, γδ T cells, and T helper cell subsets. Three IPFG-based clusters exhibited distinct immune microenvironments, pathway activities and programmed cell death profiles. Integration of transcriptomic and immune features yielded a combined diagnostic nomogram with an AUC of 0.970. Single-cell analysis revealed cell type-specific expression of IPFGs, with CCL2 enriched in macrophages and fibroblasts and SYDE2 and COL4A3 enriched in alveolar epithelial cells. GSEA revealed that key IPFGs were involved in JAK/STAT, WNT, TGF-β, and Toll-like receptor signaling pathways.
conclusionsThis integrative multiomics analysis delineates key immunometabolic circuits involved in IPF pathogenesis and treatment. The identified IPFGs represent both mechanistic drivers and predictive biomarkers, offering translational potential for immunomodulatory therapies and clinical stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.